Article
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
European journal of gastroenterology & hepatology - 1 Jan 2022
Stein Kerstin, Stoehr Albrecht, Klinker Hartwig, Teuber Gerlinde, Naumann Uwe, John Christine, Heyne Renate, Serfert Yvonne, Niederau Claus, Zeuzem Stefan, Berg Thomas, Wiegand Johannes
Abstract excerpt
OBJECTIVES: Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min. Both therapies have been separately analyzed in different real-life cohorts; however, a direct comparison has not been performed so far. We, therefore, analyzed safety and effectiveness of both...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.